KDNYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (11 8月 2023 @ 05:00):

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases...

Stats
本日の出来高	3.28M
平均出来高	2.04M
時価総額	2.71B
EPS	$0 ( 2024-02-26 )
次の収益日	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.47
ATR14	$0.453 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Thomas Dolca	Sell	13 300	Common Stock
2023-08-11	Thomas Dolca	Sell	23 522	Stock Option (Right to Buy)
2023-08-11	Thomas Dolca	Sell	5 948	Stock Option (Right to Buy)
2023-08-11	Thomas Dolca	Sell	13 300	Stock Option (Right to Buy)
2023-08-11	Oxtoby Andrew	Sell	160 000	Stock Option (Right to Buy)

INSIDER POWER
-96.01
Last 99 transactions
Buy: 289 232 \| Sell: 10 194 260

ボリューム相関

長: 0.28 (neutral)

短: 0.00 (neutral)

Signal:(78.495) Neutral

Aduro Biotech Inc 相関

10 最も正の相関
COLL	0.876
GLMD	0.873
BCDA	0.868
EVER	0.865
EEIQ	0.86
CNXC	0.86
ATIF	0.857
AGNC	0.856
ABIO	0.853
DADA	0.848

10 最も負の相関
RMRM	-0.904
MTEK	-0.902
APR	-0.88
APP	-0.859
MMAC	-0.857
NGMS	-0.85
AAPL	-0.845
RBKB	-0.843
RIBT	-0.842
COUP	-0.841

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aduro Biotech Inc 相関 - 通貨/商品

-0.16
( neutral )

0.56
( weak )

0.54
( weak )

0.03
( neutral )

0.39
( neutral )

0.20
( neutral )

Aduro Biotech Inc 財務諸表

Annual	2022
収益:	$6.13M
総利益:	$4.41M (71.90 %)
EPS:	$-2.87

FY	2022
収益:	$6.13M
総利益:	$4.41M (71.90 %)
EPS:	$-2.87

FY	2021
収益:	$51 625.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00226

FY	2020
収益:	$827 000
総利益:	$827 000 (100.00 %)
EPS:	$-6.20

Financial Reports:

No articles found.

Aduro Biotech Inc

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.